Heat Biologics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Heat Biologics, Inc. - overview
Established
2008
Location
Morrisville, NC, US
Primary Industry
Biotechnology
About
Heat Biologics, Inc. is a biopharmaceutical company focused on developing innovative immune-oncology therapies to treat cancer, leveraging proprietary technology to stimulate the immune system against tumors. Founded in 2008 in Morrisville, US, Heat Biologics, Inc. specializes in the development of immune-oncology treatments.
The company has raised a total of USD 25. 00 mn through its IPO on July 23, 2013, selling 2. 5 million shares at USD 10 each. It has completed a total of 6 deals, and all VC investors have exited their stake in the company.
Heat Biologics, Inc. focuses on creating immunotherapies that aim to enhance the immune response against cancer cells. Their product offerings include innovative therapies designed to stimulate the body's immune system, providing solutions aimed at improving patient outcomes in oncology. These therapies are targeted towards healthcare providers and institutions involved in cancer treatment.
For the most recent fiscal year 2024, Heat Biologics, Inc. reported a revenue of USD 6,243,022. The company's EBITDA for the same year was USD -26,446,112, reflecting their ongoing investment in research and development activities in the biopharmaceutical sector. Following its recent IPO, Heat Biologics, Inc.
plans to utilize the raised USD 25 mn to further develop its immune-oncology product pipeline and expand clinical trials. The company is targeting specific markets in North America and Europe for upcoming launches of new therapies in the next few years, aiming to enhance its treatment offerings and improve patient access to innovative cancer therapies.
Current Investors
Seed-One Ventures, UM Innovation, BrightLine
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.heatbio.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Heat Biologics, Inc. - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | 341,643 | 1,519,943 | 5,793,849 | 3,049,104 | 2,947,969 | 2,112,806 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | 344.9% | 281.2% | (47.4%) | (3.3%) | (28.3%) | - | - | - |
| EBITDA (USD) | (6,479,283) | (11,909,272) | (20,663,000) | (12,743,682) | (13,208,765) | (17,722,995) | (20,513,299) | (25,791,210) | (34,811,372) | - | - | - |
| Operating Income (USD) | (6,564,641) | (12,186,927) | (21,022,000) | (13,127,319) | (13,342,849) | (17,960,313) | (20,745,805) | (26,124,362) | (35,419,039) | - | - | - |
| Operating Margin | - | - | - | (3842.4%) | (877.9%) | (310.0%) | (680.4%) | (886.2%) | (1676.4%) | - | - | - |
| % EBITDA Margin | - | - | - | (3730.1%) | (869.0%) | (305.9%) | (672.8%) | (874.9%) | (1647.6%) | - | - | - |
| NET Income (USD) | (6,609,864) | (12,243,211) | (21,122,000) | (12,974,799) | (12,409,866) | (16,591,293) | (20,384,716) | (26,381,389) | (35,400,807) | - | - | - |
| % Net Margin | - | - | - | (3797.8%) | (816.5%) | (286.4%) | (668.5%) | (894.9%) | (1675.5%) | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.